Achilles Therapeutics plc(ACHL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACHL Achilles Therapeutics plc

Market Closed 12-20 16:00:00 EST

0.9811

+0.0011

+0.11%

盘后0.9800

-0.0011-0.11%

16:40 EST

High0.9900	Low0.9601	Vol123.02K
Open0.9900	D1 Closing0.9800	Amplitude3.05%
Mkt Cap40.32M	Tradable Cap20.45M	Total Shares41.10M
T/O120.32K	T/O Rate0.59%	Tradable Shares20.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ACHL","market":"US","secType":"STK","nameCN":"Achilles Therapeutics plc","latestPrice":0.9811,"timestamp":1734728400000,"preClose":0.98,"halted":0,"volume":123015,"hourTrading":{"tag":"盘后","latestPrice":0.98,"preClose":0.9811,"latestTime":"16:40 EST","volume":1000,"amount":980,"timestamp":1734730804773},"delay":0,"floatShares":20846269,"shares":41100040,"eps":-1.658963,"marketStatus":"Market Closed","change":0.0011,"latestTime":"12-20 16:00:00 EST","open":0.99,"high":0.99,"low":0.9601,"amount":120322.687559,"amplitude":0.03051,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.658963,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1617163200000,"exchange":"NASDAQ","adjPreClose":0.98,"preHourTrading":{"tag":"盘前","latestPrice":0.97,"preClose":0.9859,"latestTime":"08:38 EST","volume":10604,"amount":10287.014628,"timestamp":1734701921001},"postHourTrading":{"tag":"盘后","latestPrice":0.98,"preClose":0.9811,"latestTime":"16:40 EST","volume":1000,"amount":980,"timestamp":1734730804773},"volumeRatio":0.6580939425699002},"requestUrl":"/m/hq/s/ACHL","defaultTab":"news","newsList":[{"id":"2487057733","title":"Achilles Therapeutics Reports Q3 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2487057733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487057733?lang=en_us&edition=fundamental","pubTime":"2024-11-29 11:50","pubTimestamp":1732852256,"startTime":"0","endTime":"0","summary":"Achilles Therapeutics Plc ( ($ACHL) ) has released its Q3 earnings. Here is a breakdown of the information Achilles Therapeutics Plc presented to i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/achilles-therapeutics-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/achilles-therapeutics-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","ACHL"],"gpt_icon":0},{"id":"2484948573","title":"Achilles Therapeutics receives approval to transfer to Nasdaq Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2484948573","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484948573?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:10","pubTimestamp":1732018221,"startTime":"0","endTime":"0","summary":"Achilles Therapeutics (ACHL) announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market approved the Com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/achilles-therapeutics-receives-approval-to-transfer-to-nasdaq-capital-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/achilles-therapeutics-receives-approval-to-transfer-to-nasdaq-capital-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ","IE00B3QW5Z07.USD","QLD","QID","NDAQ","BK4588","TQQQ","IE00B64PRP62.GBP","BK4585",".IXIC","LU2210149790.SGD","NQmain","BK4112","ACHL","BK4139","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","LU2095319765.USD","BK4539","LENZ","SQQQ","MNQmain"],"gpt_icon":0},{"id":"2484062910","title":"BRIEF-Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2484062910","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484062910?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:04","pubTimestamp":1732017866,"startTime":"0","endTime":"0","summary":"Nov 19 (Reuters) - Achilles Therapeutics PLC   :   * ACHILLES THERAPEUTICS RECEIVES APPROVAL TO TRANSFER TO NASDAQ CAPITAL MARKET   * ACHILLES THERAPEUTICS PLC - TRANSFER EFFECTIVE NOVEMBER 19, 2024Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SQQQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","TQQQ",".IXIC","BK4139","LENZ","NDAQ","QID","NQmain","BK4112","IE00B3QW5Z07.USD","MNQmain","LU2210149790.SGD","LU2095319765.USD","PSQ","ACHL","QLD","BK4585","BK4588"],"gpt_icon":0},{"id":"2484591006","title":"Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2484591006","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484591006?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:00","pubTimestamp":1732017600,"startTime":"0","endTime":"0","summary":"LONDON, Nov.  19, 2024  (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of theNasdaq Stock Market LLC(\"Nas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/19/2983431/0/en/Achilles-Therapeutics-Receives-Approval-to-Transfer-to-Nasdaq-Capital-Market.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QID","BK4112","NQmain","BK4139","BK4539","ACHL","BK4585","LU2210150020.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","MNQmain","IE00BGHQF748.EUR","LENZ","SQQQ","LU2210149790.SGD","NDAQ","QLD","TQQQ","IE00B3QW5Z07.USD","PSQ","LU2095319765.USD",".IXIC","BK4588"],"gpt_icon":1},{"id":"2483232802","title":"Achilles Therapeutics Explores Strategic Options Amid Financial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483232802","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483232802?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:54","pubTimestamp":1731596049,"startTime":"0","endTime":"0","summary":"Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has reported a cash position of $86.1 million as of September 30, 2024, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/achilles-therapeutics-explores-strategic-options-amid-financial-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/achilles-therapeutics-explores-strategic-options-amid-financial-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","ACHL"],"gpt_icon":0},{"id":"2483480969","title":"Achilles Therapeutics PLC reports results for the quarter  - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483480969","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483480969?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:15","pubTimestamp":1731593759,"startTime":"0","endTime":"0","summary":"Achilles Therapeutics PLC reports results for the quarter  - Earnings SummaryAchilles Therapeutics PLC ACHL.OQ reported a quarterly adjusted loss of 48 cents per share for the quarter , lower than the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL8N3ML1WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACHL"],"gpt_icon":0},{"id":"2483744728","title":"Achilles Therapeutics Q3 2024 GAAP EPS $(0.48), Inline, Cash Position Of $86.1M","url":"https://stock-news.laohu8.com/highlight/detail?id=2483744728","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483744728?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:43","pubTimestamp":1731588237,"startTime":"0","endTime":"0","summary":"Achilles Therapeutics (NASDAQ:ACHL) reported quarterly losses of $(0.48) per share which met the analyst consensus estimate. This is a 14.29 percent decrease over losses of $(0.42) per share from the same period last","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41969482/achilles-therapeutics-q3-2024-gaap-eps-0-48-inline-cash-position-of-86-1m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ACHL"],"gpt_icon":0},{"id":"2481839314","title":"Achilles Therapeutics PLC  expected to post a loss of 41 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2481839314","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481839314?lang=en_us&edition=fundamental","pubTime":"2024-11-08 23:46","pubTimestamp":1731080793,"startTime":"0","endTime":"0","summary":"Achilles Therapeutics PLC  expected to post a loss of41cents a share - Earnings Preview Achilles Therapeutics PLC ACHL.OQ, ACHL.O is expected to show no change in quarterly revenue when it reports  re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF238:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACHL"],"gpt_icon":0},{"id":"2469114628","title":"European Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2469114628","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469114628?lang=en_us&edition=fundamental","pubTime":"2024-09-23 23:27","pubTimestamp":1727105271,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were edging up on Monday morning, up 0.1% to 1,439.10 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by tech company Opera  and food company Oatly , which rose 4% and 3.4% respectively. They were followed by petroleum refining company Equinor , which climbed 1.8%.The decliners from continental Europe were led by pharmaceutical giant Novo Nordisk  and Ascendis Pharma , which fell 2.9% and 2.6% respectively. They were followed by pharmaceutical and chemical manufacturer Grifols , which dropped 2.5%.From the UK and Ireland, the gainers were led by cryptocurrency miner Argo Blockchain  and banking and financial services provider HSBC , which rose 3.6% and 1.9% respectively.The decliners from the UK and Ireland were led by biotech companies Autolus Therapeutics  and Achilles Therapeutics , which shed 6.2% and 3.9% respectively.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","HSBA.UK","HSBC","BK1572","OPRA","ACHL","BK4548","BK4521","03143","BK4117","BK4212","LU1481107354.HKD","BK4007","IE00BKVL7J92.USD","LU0109394709.USD","BK4107","AUTL","BK4207","LU0540923850.HKD","BK1601","BK1231","BK4539","LU0417516738.SGD","OTLY","IE00BZ1G4Q59.USD","BK4588","BK1610","LU0634319403.HKD","00005","GRFS","BK7104","LU0348735423.USD","LU0149721374.USD","EQNR","BK4585","AFG","LU0320765992.SGD","LU2308191902.HKD","ARBK","ASND","BK4201","NVO","LU1093756168.USD","LU2236285917.USD","BK4595","LU0164880469.USD","BK4023","BK4532","LU0154236417.USD"],"gpt_icon":1},{"id":"2469429146","title":"Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2469429146","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469429146?lang=en_us&edition=fundamental","pubTime":"2024-09-23 21:40","pubTimestamp":1727098810,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Achilles Therapeutics PLC Sponsored ADR  one of those stocks right now?Let's take a closer look at the stock's year-to-date performance to find out.Achilles Therapeutics PLC Sponsored ADR is a member of our Medical group, which includes 1016 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Achilles Therapeutics PLC Sponsored ADR is currently sporting a Zacks Rank of #2 .Another stock in","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/achilles-therapeutics-achl-stock-outpacing-134010391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","ACHL","BK4539","BK4139","BFLY"],"gpt_icon":0},{"id":"2468162752","title":"European Equities Traded in the US as American Depositary Receipts Decrease Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2468162752","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468162752?lang=en_us&edition=fundamental","pubTime":"2024-09-20 23:07","pubTimestamp":1726844828,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were falling on Friday morning, down 1.5% to 1,436.90 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech company Genfit  and telecommunications company Ericsson , which were rising 18% and 1% respectively.The decliners from continental Europe were led by Danish pharmaceutical giant Novo Nordisk  and semiconductor manufacturing company STMicroelectronics , which fell 5.9% and 4.4% respectively.They were followed by semiconductor company ASML , which declined 3.8%.From the UK and Ireland, the gainers were led by biotech companies Centessa Pharmaceuticals  and Achilles Therapeutics , which rose 3.9% and 2.8% respectively.The decliners from the UK and Ireland were led by Biodexa Pharmaceuticals  and Autolus Therapeutics , which lost 7.1% and 3.9% respectively.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7104","STM.AU","BK4591","IE00BD6J9T35.USD","CNTA","BK4020","BK4539","LU1734074674.USD","GNFT","AUTL","LU0097036916.USD","BK7095","LU1093756168.USD","NVO.AU","BK4535","BK4007","AFG","BK4141","LU0154236417.USD","NVO","IE00BMPRXR70.SGD","IE00BKVL7J92.USD","BK4147","IE00BZ1G4Q59.USD","IE00BMPRXN33.USD","BK4107","BK4554","IE0004445239.USD","BK4585","BDRX","BK4139","LU1093756325.SGD","ASML","03165","LU2063271972.USD","ERIC","BK4588","BK4515","ACHL","BK4532","BK4117","STM"],"gpt_icon":1},{"id":"2468568013","title":"ADRs Close Higher; Achilles Therapeutics PLC Climbs 32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2468568013","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468568013?lang=en_us&edition=fundamental","pubTime":"2024-09-20 04:30","pubTimestamp":1726777800,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed higher on Thursday, as the S&P/BNY Mellon index of American depositary receipts added 2.3% to 187.93.The European index rose 1.6% to 183.21. The Asian index added 3.7% to 221.81. The Latin American index rose 0.7% to 199.58, while the emerging-markets index rose 3.4% to 364.58.United Kingdom's Achilles Therapeutics PLC was the biggest leader during the session, soaring 32% to 94 cents, and China-based Highest Performances Holdings Inc. surged 19% to 73 cents. Mynaric AG, which is based in Germany, rounded out the top three leaders on Thursday, with shares surging 17% to $1.28.XCHG Ltd., based in China, posted the largest decline, cratering 27% to $13.32, followed by shares of Israel's Scinai Immunotherapeutics Ltd., which cratered 20% to $3.61. Shares of China-based 36Kr Holdings Inc. plunged 16% to 20 cents.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACHL","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"2468530505","title":"Achilles Therapeutics ADRs Rise 32% on Cost-Cutting Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2468530505","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468530505?lang=en_us&edition=fundamental","pubTime":"2024-09-19 22:43","pubTimestamp":1726756980,"startTime":"0","endTime":"0","summary":"American depositary receipts of Achilles Therapeutics rose 32% after the company disclosed cost-cutting measures as part of a strategic update.ADRs were trading around 94 cents. ADRs are up about 12% on the year.The clinical-stage biopharmaceutical company announced layoffs and the discontinuation of a program and two clinical trials. Achilles said it will refocus its strategy to explore further engagement with third parties who are developing alternative modalities to target clonal neoantigens for cancer treatments.Achilles also said it has engaged BofA Securities as a financial adviser in the process of exploring and reviewing value-maximizing strategies.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACHL","BK4139","BK4539","LENZ"],"gpt_icon":0},{"id":"2468365576","title":"Achilles climbs after decision to find strategic alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2468365576","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468365576?lang=en_us&edition=fundamental","pubTime":"2024-09-19 20:19","pubTimestamp":1726748353,"startTime":"0","endTime":"0","summary":"Achilles Therapeutics  ADRs added ~42% in the premarket on Thursday after the U.K.-based biotech announced plans to explore strategic alternatives and close its CHIRON and THETIS clinical trials for its lead T cell therapy candidate. Concurrently, Achilles  announced a program for workforce reduction and several cost-cutting measures. The strategic alternatives it plans to explore include an acquisition, merger, reverse merger, business combination, the London-headquartered firm said. The Phase I/IIa CHIRON and THETIS trials targeted advanced non-small cell lung cancer and recurrent or metastatic melanoma. As the T-cell monotherapy trials conclude, the company said it will present their full clinical data at a future medical meeting. Achilles  added that as part of its strategic refocus, it will seek engagement with developers advancing alternative cancer treatment options, such as antibody-drug conjugates and neoantigen vaccines. The company recorded $95.1M in cash and cash equivalent","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1456010293/image_1456010293.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1456010293/image_1456010293.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4151050-achilles-stock-climbs-strategic-focus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BK4539","ACHL"],"gpt_icon":0},{"id":"2468758185","title":"Achilles Therapeutics Discontinues cNeT Program and Closes Early-to-Mid Stage Studies For Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2468758185","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468758185?lang=en_us&edition=fundamental","pubTime":"2024-09-19 20:04","pubTimestamp":1726747486,"startTime":"0","endTime":"0","summary":"Achilles Therapeutics  said Thursday that it is discontinuing its TIL-based cNeT program and closing the phase I/II clinical trials for non-small cell lung cancer treatment.The company said it would change its strategy to pursue partnerships with third parties developing alternative treatments for clonal neoantigens, such as neoantigen vaccines, ADCs, and TCR-T therapies.Achilles has also hired BofA Securities to investigate value-maximizing strategies.As of June 30, 2024, the company had $95.1 million in cash.The company said it would also reduce its workforce and implement cost-cutting measures while retaining key employees for the strategic review.Shares of the company were up nearly 47% in recent Thursday premarket activity.Price: 1.0200, Change: +0.33, Percent Change: +47.29","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4539","ACHL","SSI"],"gpt_icon":0},{"id":"2468257387","title":"Achilles Therapeutics Shifts Strategy, Seeks Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2468257387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468257387?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:47","pubTimestamp":1726746447,"startTime":"0","endTime":"0","summary":"Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has halted its TIL-based cNeT therapy development and is closing its CHI...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/achilles-therapeutics-shifts-strategy-seeks-alternatives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/achilles-therapeutics-shifts-strategy-seeks-alternatives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","ACHL","BK4505","BK4139"],"gpt_icon":0},{"id":"2468957821","title":"Achilles Therapeutics to Lay Off Staff as Part of Review, Discontinues Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2468957821","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468957821?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:44","pubTimestamp":1726746240,"startTime":"0","endTime":"0","summary":"Achilles Therapeutics said it will begin cost-cutting measures, including layoffs, as part of its strategic update,  and that it was canceling its two cancer drug trial programs.The London, U.K.-based, New York-listed clinical-stage biopharmaceutical said Thursday that it has also engaged Bank of America Securities as a financial advisor to explore and review value-maximizing strategies.\"The process of exploring strategic alternatives may include, but is not limited to, an acquisition, merger, reverse merger, business combination, asset sale, licensing, or other transactions,\" it said.As of June 30, Achilles Therapeutics said it had $95.1 million in cash and cash equivalents.The company also said it has discontinued its TIL-based cNeT program and closed the phase 1/2a Chiron and Thetis clinical trials after studies didn't meet their goals for commercial viability.The TIL-based cNeT program stands for tumor infiltrating lymphocyte-based clonal neoantigen reactive T-cell, a treatment tha","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACHL","BK4139","LENZ"],"gpt_icon":0},{"id":"2468189578","title":"BRIEF-Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2468189578","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468189578?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:40","pubTimestamp":1726746018,"startTime":"0","endTime":"0","summary":"Sept 19  - Achilles Therapeutics PLC   :   * ACHILLES THERAPEUTICS ANNOUNCES STRATEGIC UPDATE   * ACHILLES THERAPEUTICS PLC: ACHILLES TO DISCONTINUE DEVELOPMENT OF TIL-BASED CNET THERAPY   * ACHILLES THERAPEUTICS PLC SAYS BOFA SECURITIES ENGAGED TO PROVIDE STRATEGIC FINANCIAL ADVICE   * ACHILLES THERAPEUTICS PLC: PROPOSING A WORKFORCE REDUCTION   * ACHILLES THERAPEUTICS PLC SAYS  AS OF JUNE 30, 2024, COMPANY HAD $95.1 MILLION IN CASH AND CASH EQUIVALENTS   * ACHILLES THERAPEUTICS: EXPLORING STRATEGIC ALTERNATIVES MAY INCLUDE ACQUISITION, MERGER, REVERSE MERGER, BUSINESS COMBINATION, ASSET SALE, LICENSING   * ACHILLES THERAPEUTICS PLC: TO EXPLORE ENGAGEMENT WITH THIRD PARTIES THAT DEVELOP ALTERNATIVE MODALITIES TO TARGET CLONAL NEOANTIGENS   * ACHILLES THERAPEUTICS PLC: INTENDS TO RETAIN ALL EMPLOYEES ESSENTIAL FOR SUPPORTING VALUE-REALIZATION AS PART OF STRATEGIC REVIEWSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACHL","BK4505","LENZ","BK4539"],"gpt_icon":1},{"id":"2468200615","title":"Syncona’s Achilles to Refocus Strategy After Program Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2468200615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468200615?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:10","pubTimestamp":1726744216,"startTime":"0","endTime":"0","summary":"Syncona Shs GBP (GB:SYNC) has released an update. Syncona Ltd, a leading life science investor, reports that Achilles Therapeutics, in which it hol...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/synconas-achilles-to-refocus-strategy-after-program-cancellation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/synconas-achilles-to-refocus-strategy-after-program-cancellation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","ACHL","BK4139"],"gpt_icon":0},{"id":"2468527630","title":"Achilles Therapeutics Announces Strategic Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2468527630","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468527630?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:00","pubTimestamp":1726743600,"startTime":"0","endTime":"0","summary":"–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice–    LONDON, Sept.  1","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/19/2948865/0/en/Achilles-Therapeutics-Announces-Strategic-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ACHL","BK4139","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.achillestx.com","stockEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":-0.0831},{"period":"3month","weight":-0.0566},{"period":"6month","weight":0.1488},{"period":"1year","weight":0.1815},{"period":"ytd","weight":0.1036}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.060793},{"month":2,"riseRate":0.333333,"avgChangeRate":0.059168},{"month":3,"riseRate":0,"avgChangeRate":-0.098119},{"month":4,"riseRate":0,"avgChangeRate":-0.20962},{"month":5,"riseRate":0.75,"avgChangeRate":0.092458},{"month":6,"riseRate":0.25,"avgChangeRate":-0.096448},{"month":7,"riseRate":0.75,"avgChangeRate":-0.074069},{"month":8,"riseRate":0.5,"avgChangeRate":0.021151},{"month":9,"riseRate":0.5,"avgChangeRate":0.080111},{"month":10,"riseRate":0,"avgChangeRate":-0.108069},{"month":11,"riseRate":0.5,"avgChangeRate":-0.021821},{"month":12,"riseRate":0.25,"avgChangeRate":-0.145795}],"exchange":"NASDAQ","name":"Achilles Therapeutics plc","nameEN":"Achilles Therapeutics plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Achilles Therapeutics plc(ACHL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Achilles Therapeutics plc(ACHL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Achilles Therapeutics plc,ACHL,Achilles Therapeutics plc股票,Achilles Therapeutics plc股票老虎,Achilles Therapeutics plc股票老虎国际,Achilles Therapeutics plc行情,Achilles Therapeutics plc股票行情,Achilles Therapeutics plc股价,Achilles Therapeutics plc股市,Achilles Therapeutics plc股票价格,Achilles Therapeutics plc股票交易,Achilles Therapeutics plc股票购买,Achilles Therapeutics plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Achilles Therapeutics plc(ACHL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Achilles Therapeutics plc(ACHL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}